Fund profile by ISIN IE00BYZK4776
iShares Healthcare Innovation UCITS ETF
Research iShares Healthcare Innovation UCITS ETF by ISIN IE00BYZK4776: TER 0.40%, domicile Ireland, accumulating, and 1-year price performance +34.4%.
ISINIE00BYZK4776
TER0.40%
DomicileIreland
Distribution policyAccumulating
Index—
Fund size1.1B
Holdings—
1-year price performance+34.4%
Exchange listings and tradability
| Ticker | Exchange | Currency | Country | Avg daily turnover | Avg daily shares |
|---|---|---|---|---|---|
| 2B78.DE | XETRADefault at German brokers | EUR | Ireland | €804K | 95,062 |
| HEAL.MI | ETFP | EUR | Ireland | €674K | 78,107 |
| HEAL.L | LSE | USD | Ireland | €545K | 65,006 |
| DRDR.L | LSE | GBX | Ireland | €373K | 44,616 |
| HEAL.AS | XAMS | EUR | Ireland | €229K | 26,839 |
| HEAL.SW | SW | USD | Ireland | €170K | 20,143 |
Avg daily turnover is the 90-day average, converted to euros so venues in different currencies can be compared; avg daily shares is the same window in units. The most traded listing is shown first. This fund trades on a German exchange. As of 2026-08-28.
Largest holdings
The 10 largest holdings make up 15.79% of the fund. As of 2026-08-11.
| Holding | Symbol | Weight |
|---|---|---|
| Moderna Inc | MRNA | 1.99% |
| Roivant Sciences Ltd Ordinary Shares | ROIV | 1.66% |
| Natera Inc | NTRA | 1.66% |
| Guardant Health Inc | GH | 1.57% |
| AbbVie Inc | ABBV | 1.52% |
| Genmab AS | GMAB.CO | 1.50% |
| Illumina Inc | ILMN | 1.49% |
| Lonza Group Ltd | LONN.SW | 1.48% |
| Biogen Inc | BIIB | 1.47% |
| Merck & Co Inc | MRK | 1.46% |
Performance is the historical price return of the representative listing. Distributions are excluded and past performance is not a forecast.